Best Life Sciences Companies in Rehovot, Israel
The 76 best Life Sciences companies in Rehovot, Israel in 2026, ranked by funding and momentum. Funding, investors, founders, valuation, tech stack and live signals. Top: NeoTX.
Our analysis of 50 Life Sciences companies
$2.2b in tracked funding; 75% of the stack-profiled cohort runs cloud-native; funding activity peaked in 2024.
Ranked: Best Life Sciences companies in Rehovot
| # | Company | Disclosed funding | Last round | Employees | Founder | Stage | Tech stack | Patents & IP focus | Recent signals |
|---|---|---|---|---|---|---|---|---|---|
| 1 | NeoTX Combinational tumor-targeting protein drugs for cancer | $101M | 76 mo ago | 33 | Asher Nathan CEO | Series C | — | — | — |
| 2 | Nucleix Developer non-invasive molecular cancer diagnostic tests | $88M | 53 mo ago | 62 | — | Series C | WordPressApple iCloud MailMicrosoft 365+24 | 163 patents Epigenetic DNA methylation profiling for cancer and prenatal liquid biopsy diagnostics. | — |
| 3 | Equinom AI-powered grain optimization for smarter milling and enhanced food production | $71M | 42 mo ago | 43 | Gil Shalev Founder & CEO | Series D | Webflowcore-jsjQuery+16 | — | 1 launch |
| 4 | Foamix Developer of proprietary dermatology therapuetics | $66M | 82 mo ago | 81 | Meir Eini Founder | Public | — | 284 patents Pharmaceutical and cosmetic foamed delivery systems for topical antibiotics and rheology control | — |
| 5 | SciVac Therapeutics Developed vaccine for hepatitis B | $54M | 131 mo ago | — | Curtis Lockshin CEO | Acqui-Hired | WordPressApple iCloud MailMicrosoft 365+19 | — | — |
| 6 | D-Pharm Drug re-engineering technology to develop new drugs for CNS indications | $48M | 241 mo ago | 76 | Ofra Yamin CEO | Series D | — | — | — |
| 7 | SteadyMed Therapeutic drug-device combinations | $44M | 110 mo ago | 24 | — | Acquired | — | 95 patents Drug infusion devices and formulations for pulmonary arterial hypertension therapy | — |
| 8 | Pi-Cardia Developer of non-implant device for valve repair | $40M | 74 mo ago | 50 | Erez Golan Co-Founder & CEO | Series D | WixSentryBootstrap+11 | 62 patents Transcatheter devices for cutting, fracturing, and expanding heart valve tissue and prostheses | 1 partnership |
| 9 | Biomica Developer of microbiome-based therapeutics to treat immune-mediated and infectious diseases | $20M | 37 mo ago | 15 | Elran Haber CEO | Series B | WordPressMySQLPHP+16 | 38 patents Therapeutic and diagnostic microbial consortia for human health applications | — |
| 10 | Laminate Medical Device to prevent AV Fistula failure by promoting their maturation and patency | $20M | 80 mo ago | 20 | Eyal Orion Co-Founder & Board Member | Series C | WordPressMySQLPHP+14 | — | 2 partnerships |
| 11 | ImmunArray Microarray-based in vitro diagnostics for autoimmune diseases | $15M | 96 mo ago | 30 | — | Series B | — | 13 patents Diagnostic assays for systemic lupus erythematosus using protein, peptide and oligonucleotide biomarkers | — |
| 12 | Curesponse Provider of a tissue culture system to analyze cancer growth and drug response | $14M | 55 mo ago | 16 | Guy Neev Co-Founder & CEO | Series B | WordPressMySQLPHP+17 | — | — |
| 13 | Lavie Bio Provider of microbiome-based agricultural biological products for improving food quality, sustainability, and… | $10M | 46 mo ago | 23 | Ofer Haviv CEO | Acquired | WordPressMySQLPHP+15 | 37 patents Microbial biocontrol agents and formulations for crop disease and pest management | — |
| 14 | Todos Medical Developer of in vitro diagnostics for the detection of cancer and neurodegenerative disorders | $7M | 57 mo ago | 7 | — | Public | — | 42 patents Blood-based infrared spectroscopy for Alzheimer’s and cancer biomarker detection | — |
| 15 | Pigmentum Developer of genetically modified plants producing natural compounds | $7M | 40 mo ago | 9 | Tal Lutzky Co-Founder & CEO | Deadpooled | — | — | — |
| 16 | ImmunoBrain Developer of neuroprotective immune therapies for neurodegenerative diseases | $5M | 57 mo ago | 14 | Michal Schwartz Co-Founder | Funding Raised | WordPressMySQLPHP+18 | — | — |
| 17 | MyBiotics Developer of microbiome-based therapeutics to treat various diseases | $5M | 48 mo ago | 27 | David Daboush Co-Founder & CEO | Seed | — | — | — |
| 18 | Efranat Cancer immunotherapies based on glycoprotein mimics | $4M | 139 mo ago | 13 | Uri Yogev CEO | Series A | — | 19 patents Immunomodulatory biologics targeting macrophage activation for cancer and papilloma therapy | — |
| 19 | Ovalum Vascular Solutions for chronic and acute total occlusions in the coronary and peripheral arteries. | $4M | 237 mo ago | — | Noam Shamay Founder & CEO | Deadpooled | — | — | — |
| 20 | ProChon Biotech Develops and commercializes regenerative biology-based products for acute and chronic articular cartilage… | $4M | 197 mo ago | — | Patrick O'Donnell CEO | Acqui-Hired | — | 88 patents Engineered fibroblast growth factor (FGF) protein variants for targeted therapeutic applications | — |
| 21 | Algocell Provider of AI-powered bioprocess optimization solutions 27Talent top 38%AI top 45%Tech top 49%Funding bottom 42% All 6 signals ▾Talenttop 38% AItop 45% Techtop 49% Fundingbottom 42% Globalbottom 32% Marketbottom 25% Talent: 2 named leaders on record · 2 C-suite/founder profiles curated AI: Product described with: ai-powered rank vs industry peers · Fliar Intelligence Index 27/100 | $3M | 11 mo ago | — | Omri Schanin Co-Founder & CEO | Seed | WordPressMySQLPHP+21 | — | — |
| 22 | Predictive Therapeutics Developing tumor-cell coating molecules as therapy for cancer | $2M | 128 mo ago | — | Asher Nathan Co-Founder & CEO | Series A | — | — | — |
| 23 | PerfAction Developing nonsurgical face lifting, skin regeneration and scar repair treatments | $2M | 189 mo ago | 15 | — | Seed | — | — | — |
| 24 | TechnoPulm Platform offering solutions for lung function diagnostics | $2M | 20 mo ago | — | Igor Krivts Co-Founder | Seed | — | 12 patents Pulmonary function testing and exhaled gas analysis devices for respiratory diagnostics | — |
| 25 | Evogene Developer of computational tools for pharmaceutical and agricultural industries | $2M | 37 mo ago | 137 | — | Public | WordPressMySQLPHP+22 | 1,226 patents Genetically engineered plant traits for enhanced yield, biomass, nitrogen use, and stress tolerance | 1 partnership |
| 26 | Eximo Medical Hybrid catheters for vascular procedures | $2M | 130 mo ago | 15 | — | Acquired | — | 74 patents Patents concentrated in health & consumer products | — |
| 27 | Formulex Developer of cannabinoid drug products | $1M | 208 mo ago | — | Galia Krayz CEO | Series A | — | — | — |
| 28 | Biokine Therapeutics Developing CXCR4 antagonist drugs for cancer | $1M | 207 mo ago | — | Amnon Peled Co-Founder & CEO | Funding Raised | — | 263 patents Peptide-based cancer therapeutics targeting tumor growth and immune modulation | — |
| 29 | Gerium Medical Non-Invasive transcutaneous bilirubin meter for the diagnosis of neonatal jaundice | $986K | 171 mo ago | 4 | Moshe Gerber CEO | Acqui-Hired | — | — | — |
| 30 | TargetGene Biotechnologies Platform for in-vivo assembling of nucleases in plant cells | $930K | 38 mo ago | 6 | Dan Weinthal Co-Founder And Coo | Funding Raised | — | 46 patents CRISPR-based gene editing platforms for immune cell engineering and targeted DNA modification | — |
| 31 | Rosetta Green Provider of tech news, computer repair tips, and gadget information | $814K | 178 mo ago | — | Aviad Friedman Chairman & CEO | Acquired | — | 12 patents Genetically engineered crops improving oil yield, stress tolerance, and nitrogen efficiency | — |
| 32 | IDEA Biomedical Biological cell imaging system for drug discovery | $669K | 93 mo ago | — | Shlomo Turgeman Founder & CEO | Funding Raised | WordPressMySQLPHP+40 | 13 patents Automated optical focusing and high-throughput plate imaging for biomedical assays. | — |
| 33 | Semorex Research-based company developing therapeutics for treatment of cancer | $327K | 218 mo ago | — | Maghsoud Dariani CEO & President | Acqui-Hired | — | 10 patents Diagnostic fungal detection kits and chemiluminescent polymer therapeutics for proliferative diseases | — |
| 34 | Elfi-Tech Developing technology for non-invasive physiological monitoring and diagnostics | $113K | 86 mo ago | 14 | Ilya Fine Founder & CEO | Funding Raised | — | 42 patents Non‑invasive optical blood‑pressure and hemodynamic monitoring using dynamic light scattering | — |
Top 12 Life Sciences companies in Rehovot
#1
Seed · Rehovot, Central District · founded 2023$2.8Mraised▾
Provider of AI-powered bioprocess optimization solutions. It uses hybrid models, digital twins, and advanced AI technologies to accelerate bioprocess development and scale-up. The platform allows users to upload data, calibrate models, and create digital twins for gaining insights into cell line metabolism, optimizing protocols, and ensuring seamless transitions from pilot to manufacturing. This approach reduces trial-and-error experimentation, improves cell productivity, and enables real-time optimization during production. Key technologies include engineering models, data intelligence, design of experiments, AI optimization algorithms, and hybrid biological models.
- Jul 2025Seed$2.8M
- Jul 2025Grant (prize money)—
#2
Seed · Rehovot, Central District · founded 2016$2Mraised▾
Platform offering solutions for lung function diagnostics. It provides a devices for pulmonary function testing, enabling accurate and portable lung function diagnostics at the doctors office or patients home. The flagship product, the TechnoPulm system, offers cabinless plethysmography, spirometry, and CO2 fractional exhaled nitrous oxide testing for complete PFT. It aims to enhance patient monitoring and management of respiratory diseases.
- Oct 2024Seed$500K
#3
Series D · Rehovot, Central District · founded 2012 · 43 employees$71Mraised▾
AI-powered grain optimization for smarter milling and enhanced food production. They are revolutionizing the food industry by developing and optimizing grain crops using cutting-edge AI technology. Their Manna™ AI software empowers millers, traders, and ingredient processors to make informed decisions, improve purchasing power, enhance storage efficiency, and boost processing output. This SaaS platform analyzes grain properties, predicts performance, and provides actionable insights to save money, predict quality, boost operational efficiency, and reduce risk. They also breed innovative non-GMO crop varieties to meet specific food industry needs, driving food innovation from plant to plate. Their solutions optimize protein-crop processing and wheat baking quality, shaping the grain value chain with data-driven insights and precision.
- Dec 2022Series D$35M
- Jun 2021Series C$20M
- Jan 2020Grant (prize money)$160.8K
- Dec 2019Series B$10M
#4
Series C · Rehovot, Central District · founded 2008 · 62 employees$88.5Mraised▾
Developer non-invasive molecular cancer diagnostic tests. The company uses DNA methylation patterns (epigenetics) to detect cancer using proprietary biomarker assays. Its first product, the Bladder EpiCheck is used to diagnose bladder cancer. In addition, the company has developed diagnostic tests for colorectal cancer and lung cancer.
- Dec 2021Series C$22M
- Apr 2021Grant (prize money)$60.6K
- Apr 2021Series C$55M
- Nov 2018Grant (prize money)$2.8M
#5
Series B · Rehovot, Central District · founded 2017 · 15 employees$20Mraised▾
Developer of microbiome-based therapeutics to treat immune-mediated and infectious diseases. The company uses PRISM a proprietary computational analysis and predictive capabilities to identify BMC128 a combinational therapy for Non-small-cell lung carcinoma. Also, it develops drug candidates for multi drug-resistant organisms and gastrointestinal diseases.
- Apr 2023Series B$20M
#6
Series C · Rehovot, Central District · founded 2016 · 33 employees$100.9Mraised▾
NeoTX is focussed on developing immunotherapy-based late-stage cancer drugs. Its lead candidate Anyara (protein drug) is a TTS (Tumor Targeting Superantigen) which claims to increase the ability of the immune system to recognize the tumor. The candidate has finished clinical phase 1 trials for lung cancer, renal cell cancer and pancreatic cancer where it was studied as a single agent as well as in combination with docetaxel (chemotherapy). In October 2016, NeoTX entered into a partnership with Active Biotech for the development and commercialization of Anyra. As of December 2016, it is planning for a trial in combination with drugs that inhibit checkpoint dampening of the immune system.
- Feb 2020Series C$45M
- Oct 2019Series B$37.9M
- Aug 2019Series A$9.2M
- Oct 2016Series A$8.8M
#7
Public · Rehovot, Central District · founded 2001 · 81 employees$66Mraised▾
Foamix Pharmaceuticals is developing proprietary dermatology therapeutics. The company has the lead candidates: FMX101, a minocycline foam for moderate-to-severe acne in Phase III clinical trials and FMX 103 for rosacea with Phase III in progress. The company has developed a topical foam formulation for its candidates.
- Jul 2019Conventional Debt$50M
- Apr 2018Post IPO$16M
#8
Series D · Rehovot, Central District · founded 2009 · 50 employees$40Mraised▾
Pi-cardia manufactures non-implant devices for valve repair. The product Leaflex provides lines that create separation between the calcium deposits on the two sides of the scoring line, in order to regain leaflets flexibility, allow their mobility and improve valve hemodynamics.
- Apr 2020Series D$27M
- Dec 2018Series C$3M
- Jan 2016Series C$10M
#9
Acquired · Rehovot, Central District · founded 2005 · 24 employees$44.2Mraised▾
SteadyMed is a medical-device company which has developed technology for delivering high volume (>2 ml) small molecule or biologic drugs. Its stated primary focus is specialty pharma product (drug-device combination) development. Licensing of their technology is a secondary business focus. The application areas targeted currently are pulmonary arterial hypertension and at-home analgesia. The products are yet to receive FDA approval. The company went public in March 2015.
- Apr 2017Post IPO$30M
- Aug 2016Post IPO$32M
- Jan 2015Series C$12.2M
- Jun 2014Series C$19.6M
#10
Deadpooled · Rehovot, Central District · founded 2018 · 9 employees$7Mraised▾
Developer of genetically modified plants producing natural compounds. Utilizes inducible genetic mechanisms to activate gene expression in plants for metabolite production. Targets compounds such as pigments flavors aromas proteins for food pharmaceutical and cosmetic industries. Employs plants like lettuce for scalable sustainable production of high-value biomolecules.
- Jan 2023Seed$6M
- Dec 2020Seed$1M
#11
Acquired · Rehovot, Central District · founded 2019 · 23 employees$10Mraised▾
Provider of microbiome-based agricultural biological products for improving food quality, sustainability, and agricultural productivity. The company leverages cutting-edge research and development to create sustainable solutions for the agriculture industry. Its focus lies in developing novel bio-based products that improve plant health, increase yields, and reduce reliance on traditional chemical inputs. The company's innovative approach aims to address the growing global demand for food while minimizing environmental impact. Through its technology, it strives to promote sustainable farming practices and contribute to a more secure and resilient food supply chain. The company's work has a social impact by supporting farmers and promoting environmental sustainability.
- Aug 2022Series A$10M
#12
Acqui-Hired · Rehovot, Central District · founded 2005$53.8Mraised▾
SciVac Therapeutics (formerly SciGen IL) was a clinical stage company focussed on developing a vaccine for viral infections. It had developed hepatitis B (HBV) vaccine that mimics all three viral surface antigens of the hepatitis B virus which provides rapid onset of protection, high levels of anti-HBV antibodies, and can be administered at lower doses than competing HBV vaccines. The vaccine was approved in Israel and in 14 other countries . In May 2016, SciVac Therapeutics merged with VBI Vaccines and changed its name to VBI Vaccines. It's Israel unit is currently serving as contract development unit.
- Jul 2015Post IPO—
- Oct 2014Post IPO$4.4M
- Aug 2010Post IPO$274.7K
Funding & investor landscape
Notable founders
Market landscape — 10 sub-themes by coverage
Share of Life Sciences coverage by sub-theme.
Regulatory-risk over time rising
Funding & growth over time
funding rising · growth rising
How research on Biotechnology is moving in Israel
A read on the academic research around Biotechnology — which themes are gaining ground, the institutions and researchers driving them, and how the tone is shifting. Based on 267 Israel-affiliated papers.
- Ministry of Agriculture118
- Hebrew University of Jerusalem29
- Agricultural Research Organization25
- Tel Aviv University21
- Ben-Gurion University of the Negev19
- Mitochondrion1→5
- Gene1→18
- Plant disease resistance1→7
- Resistance (ecology)2→6
- Agriculture3→6
Where biotechnology is researched across Israel
Location clusters by institution affiliation — each city's volume, stance tone, and a quick read on its hot topic, what's advancing, the opening opportunity, and the main concern.
Common questions
Riya reads income statements for fun. She covers the real money in a sector — revenue, growth, who actually earns — and never met a vague claim she didn't want a number for.